Herb–drug pharmacokinetic interaction between radix astragali and pioglitazone in rats

Abstract

Ethnopharmacological relevanceRadix astragali (RA) was the most frequently used traditional Chinese medicine (TCM) according to the statistics on 52 anti-diabetic formulas recorded in New National Traditional Chinese Medicine; it was employed in 34 out of the 52 formulas. The aim of this study was to elucidate potential pharmacokinetic interaction between RA and pioglitazone, and to provide guidance for clinical medicine safety. Materials and methodsA specific and rapid UPLC–MS/MS method was established to quantify pioglitazone in rat plasma. Then healthy and type 2 diabetes mellitus (T2DM) rats were each divided into control and RA decoction (RAD) administration groups—healthy, healthy-RAD, T2DM, T2DM–RAD; pharmacokinetics of pioglitazone was carried out after RAD was administrated to rats for 7 days. ResultsThe established UPLC–MS/MS method was rapid, specific, and precise. Between healthy and healthy-RAD groups, half-life (T1/2), area under the curve (AUC 0–t), Vz/F, and Cl/F showed mild yet statistically significant differences; no significant difference for any above parameter was detected between T2DM and T2DM–RAD groups. ConclusionRAD co-administration did not affect the pharmacokinetics of pioglitazone especially in diabetic groups; RA and pioglitazone might be feasible herb–drug co-effectiveness.